Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114350 | 1.00 | MEN1 (0.43) | MEN1KMT2AALOX15TSHRALDH1A1 | |
| SCHEMBL20337332 | 0.79 | MEN1 (0.48) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL28621532 | 0.77 | ALOX15 (0.45) | MEN1KMT2AALOX15TSHRALDH1A1 | |
| SCHEMBL2115863 | 0.76 | MEN1 (0.46) | MEN1KMT2ATSHRALDH1A1KDM4E | |
| SCHEMBL242105 | 0.76 | MEN1 (0.46) | MEN1KMT2ATSHRALDH1A1KDM4E | |
| SCHEMBL2135252 | 0.75 | MEN1 (0.45) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL2116143 | 0.75 | MEN1 (0.45) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL2113888 | 0.73 | FAAH (0.54) | MEN1KMT2ATSHRKDM4ECYP1A2 | |
| SCHEMBL1965328 | 0.73 | FAAH (0.54) | MEN1KMT2ATSHRKDM4ECYP1A2 | |
| SCHEMBL2114333 | 0.73 | MEN1 (0.49) | MEN1KMT2AALDH1A1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-11903918-B2 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | BANNER LIFE SCIENCES LLC (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11590095-B2 | Fumarate ester dosage forms | BANNER LIFE SCIENCES LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2015138917-A1 | DIMETHYL FUMARATE AND VACCINATION REGIMENS | BIOGEN MA INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015128492-A1 | MONOMETHYL- AND DIMETHYLFUMARATE FOR NK CELL ACTIVATION | MAGHAZACHI AZZAM A (NO) | 2015-09-03 | — | — | WO | disclosed |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN MA INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2811994-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | Biogen Idec MA Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014190056-A2 | PRODRUGS AND DRUGS | BIOGEN IDEC MA INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN MA INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN IDEC MA INC. | 2013-08-22 | — | — | US | disclosed |
| WO-2013119677-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN IDEC MA INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | MEN1 1729/4885KMT2A 844/4885ALOX15 2505/4885 |
| US-11590095-B2 | Fumarate ester dosage forms | FH, FAH, SDHB | MEN1 1605/4885KMT2A 1091/4885ALOX15 227/4885 |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FH, SLC6A6, SLC6A13 | MEN1 1994/4885KMT2A 1926/4885ALOX15 2627/4885 |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | FH, FAH, MGMT | MEN1 414/4885KMT2A 297/4885ALOX15 1091/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | MEN1 1729/4885KMT2A 844/4885ALOX15 2505/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | MEN1 1724/4885KMT2A 797/4885ALOX15 2657/4885 |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | MEN1 455/4885KMT2A 417/4885ALOX15 1300/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | MEN1 1729/4885KMT2A 844/4885ALOX15 2505/4885 |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | MEN1 414/4885KMT2A 297/4885ALOX15 1091/4885 |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | MEN1 455/4885KMT2A 417/4885ALOX15 1300/4885 |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | MEN1 414/4885KMT2A 297/4885ALOX15 1091/4885 |
| US-11903918-B2 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | FH, SI, FAH | MEN1 518/4885KMT2A 257/4885ALOX15 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.